跳至主要内容
MedPath Trial logoMedPath TrialMedPath Trial Home
临床试验/EUCTR2015-004136-36-GB
EUCTR2015-004136-36-GB进行中（未招募）1 期

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER LONG-TERM SAFETY AND TOLERABILITY STUDY OF ETC-1002 IN PATIENTS WITH HYPERLIPIDEMIA AT HIGH CARDIOVASCULAR RISK WHO ARE NOT ADEQUATELY CONTROLLED BY THEIR LIPID-MODIFYING THERAPY - CLEAR Harmony

Esperion Therapeutics, Inc.0 个研究点目标入组 2,233 人开始时间: 2016年3月14日最近更新:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit

试验速览

阶段
1 期
状态
进行中（未招募）
入组人数
2,233
研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • •Each patient with hyperlipidemia must meet the following criteria to be randomized in this study:
  • •1. Age =18 years or legal age of majority based on regional law, whichever is greater at Week -2 (Visit S1)
  • •2. Men and nonpregnant, nonlactating women. Women must be either:
  • •Naturally postmenopausal (as reported by the patient, defined as greater than 55 years and =1 year without menses, less than 55 years and =1 year without menses with follicle-stimulating hormone (FSH) =40.0 IU/L), or surgically sterile including hysterectomy, bilateral oophorectomy, or tubal ligation or;
  • •Women of childbearing potential must be willing to use 1 acceptable method of birth control. The minimal requirement for adequate contraception it is that it should be started on Day 1, continuing during the study period, and for at least 30 days after the last dose of study drug. Acceptable methods of birth control include: oral birth control medications; placement of an intrauterine device (IUD) with or without hormones; barrier methods including condom or occlusive cap with spermicidal foam or spermicidal jelly; vasectomized male partner who is the sole partner for this patient; or true abstinence (not including periodic abstinence such as calendar, ovulation, symptothermal, postovulation methods, or withdrawal).
  • •There are no protocol-specific birth control requirements for men with partners who are able to become pregnant.
  • •3. Fasting LDL-C value at Week -2 (Visit S1) =70 mg/dL (1.8 mmol/L).
  • •Note: LDL-C may be repeated 1 time with the screening period extended up to 2 weeks. For those patients who have a repeat LDL-C, the mean of the first value and the repeat value will be used to determine eligibility.
  • •4. Have high cardiovascular risk that is defined as either:
  • •Diagnosis of HeFH. Diagnosis must be made by either genotyping or by clinical assessment using either the World Health Organization (WHO) criteria/Dutch Lipid Clinical Network Criteria with a score that is >8 points or the Simon Broome Register Diagnostic Criteria with an assessment of ‘Definite HeFH’. Patients with a diagnosis of HeFH may or may not have established CHD or CHD risk equivalents.
  • •Have ASCVD (with established CHD or CHD risk equivalents)
  • •Documented history of CHD (includes 1 or more of the following):
  • •- Acute myocardial infarction (MI)
  • •- Silent MI
  • •- Unstable angina
  • •- Coronary revascularization procedure (eg, percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery)
  • •- Clinically significant CHD diagnosed by invasive or non-invasive testing (such as coronary angiography, stress test using treadmill, stress echocardiography or nuclear imaging)
  • •Documented CHD risk equivalents (includes 1 or more of the following criteria):
  • •- Peripheral arterial disease
  • •- Previous ischemic stroke with a focal ischemic neurological deficit that persisted more than 24 hours, considered as being of atherothrombotic origin. Computed tomography (CT) or magnetic resonance imaging (MRI) must have been performed to rule out hemorrhage and non-ischemic neurological disease
  • •Note: Patients with type 2 diabetes mellitus (T2DM) are allowed in this study; however for this study T2DM is not considered a CHD risk equivalent
  • •5. Be on maximally tolerated lipid-modifying therapy, including a maximally tolerated statin either alone or in combination with other lipid-lowering therapies, at stable doses for at least 4 weeks prior to screening (6 weeks for fibrates; however, gemfibrozil i

排除标准

  • •1. Total fasting triglyceride =500 mg/dL (5.6 mmol/L) at Wk -2 (Visit S1)
  • •2. Renal dysfunction or nephritic syndrome or a history of nephritis, including eGFR (using central laboratory determined MDRD formula) <30 mL/min/1.73 m2 at Wk -2 (Visit S1).
  • •Note: Also excluded are renally impaired patients receiving an average daily dose of simvastatin 40 mg with eGFR below <45 mL/min/1.73 m2.
  • •3. BMI =50 kg/m2
  • •4. Concomitant use of simvastatin at average daily doses greater than 40 mg.
  • •5. Concomitant use of a PCSK inhibitor (alirocumab or evolocumab) at Wk -2 (Visit S1) or prior use of a PCSK9 inhibitor within the past 4 weeks of Wk -2 (Visit S1) will be excluded from this study.
  • •6. Recent (within 3 months prior to the screening visit [Wk -2 (Visit S1)] or between screening and randomization visits) MI, unstable angina leading to hospitalization, uncontrolled, symptomatic cardiac arrhythmia (or medication for an arrhythmia that was started or dose changed within 3 months of screening), CABG, PCI, carotid surgery or stenting, cerebrovascular accident, TIA, endovascular procedure or surgical intervention for peripheral vascular disease or plans to undergo a major surgical or interventional procedure (eg, PCI, CABG, carotid or peripheral revascularization). Patients with implantable pacemakers or automatic implantable cardioverter defibrillators may be considered if deemed by the Investigator to be stable for the previous 3 months.
  • •7. Uncontrolled hypertension, defined as sitting SBP =160 mmHg and DBP =100 mmHg after sitting quietly for 5 minutes.
  • •8. HbA1C =10% at Wk -2 (Visit S1)
  • •9. Uncontrolled hypothyroidism, including TSH >1.5 × ULN at Wk -2 (Visit S1). Patients stabilized on thyroid replacement therapy for at least 6 wks prior to randomization are allowed.
  • •10. Liver disease or dysfunction, including:
  • •Positive serology for HBsAg and/or HCV AB at Wk -2 (Visit S1); or
  • •ALT, AST =2 × ULN, and/or total bilirubin =1.2 × ULN at Wk -2 (Visit S1).
  • •Note: If HCV AB is positive, a reflex HCV RNA will be performed to rule out active disease. Patients without active disease may be enrolled the study.
  • •If TB =1.2 × ULN, a reflex indirect (unconjugated) bilirubin will be obtained and if consistent with Gilbert’s disease, the patient may be enrolled in the study.
  • •11. GI conditions or procedures (including weight loss surgery; eg, Lap-Band® or gastric bypass) that may affect drug absorption
  • •12. Hematologic or coagulation disorders or a Hgb level <10.0 g/dL (100 g/L) at Wk -2 (Visit S1)
  • •13. Active malignancy, including those requiring surgery, chemotherapy, and/or radiation in the past 5 yrs. Patients with a history of nonmetastatic basal or squamous cell carcinoma of the skin and cervical carcinoma in situ are allowed.
  • •14. Unexplained creatine kinase (CK) >3 × ULN at screening up to randomization (ie, not associated with recent trauma or physically strenuous activity). Patients with an explained CK elevation must have single repeat CK =3 × ULN prior to randomization.
  • •15. History within the last 2 yrs of drug, alcohol, amphetamine and derivatives, or cocaine abuse. Patients with amphetamine derivatives prescribed by and under the care of a health care practitioner can be enrolled after evaluation by the Investigator.
  • •16. Blood donation, blood transfusion for any reason, participation in a clinical study with multiple blood draws, major trauma, or surgery with or without blood loss within 30 days prior to randomization
  • •17. Use of any experimental or i

研究者

相似试验

已完成
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, COMPARATIVE, SAFETY AND EFFICACY STUDY OF INTRAVENOUS ZOLEDRONATE (4 AND 8 MG) IN PROSTATE CANCER PATIENTS WITH METASTATIC BONE LESIONS RACEIVING ANTINEOPLASTIC THERAPY
PER-011-99OVARTIS BIOSCIENSES PERÚ S.A.,
进行中（未招募）
不适用
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE SUPERIORITY OF CRX-102 OVER EACH OF ITS COMPONENTS WHEN GIVEN TO SUBJECTS WITH ACTIVE RHEUMATOID ARTHRITIS (RA)RHEUMATOID ARTHRITIS (RA)MedDRA version: 9.1Level: LLTClassification code 10039073Term: Rheumatoid arthritis
EUCTR2007-003069-42-GBCombinatoRx, Incorporated616
进行中（未招募）
1 期
A blind (not knowing which treatment to receive), placebo-controlled (with chance to receive sugar pill) study to evaluate whether brivaracetam can be used treating partial onset seizures in patients with epilepsy (= 16 to 80 years old)
EUCTR2010-019361-28-ROCB BIOSCIENCES, INC.768
进行中（未招募）
不适用
A blind (not knowing which treatment to receive), placebo-controlled (with chance to receive sugar pill) study to evaluate whether brivaracetam can be used treating partial onset seizures in patients with epilepsy (= 16 to 80 years old)
EUCTR2010-019361-28-LVCB BIOSCIENCES, INC.900
进行中（未招募）
不适用
A blind (not knowing which treatment to receive), placebo-controlled (with chance to receive sugar pill) study to evaluate whether brivaracetam can be used treating partial onset seizures in patients with epilepsy (= 16 to 80 years old)
EUCTR2010-019361-28-DECB BIOSCIENCES, INC. A Member of the UCB Group of Companies900